We are live on ! Find out more
BCM

BIOS Capital Management Portfolio holdings

AUM $52.9M
1-Year Est. Return 30.51%
This Fund
S&P 500
This Quarter Est. Return
+6.71%
1 Year Est. Return
+30.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$52.9M
AUM Growth
-$29.8M
Cap. Flow
-$209K
Cap. Flow %
-0.4%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
RNTX
Rein Therapeutics
RNTX
+$362K

Top Sells

Rank Stock Value
1
LTRN icon
Lantern Pharma
LTRN
+$406K
2
INAB icon
IN8bio
INAB
+$166K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACTU
1
Actuate Therapeutics
ACTU
$26.6M
$27.5M 52.09%
10,049,996
– –
IRD
2
Opus Genetics
IRD
$306M
$16.8M 31.7%
3,683,429
– –
CGTX icon
3
Cognition Therapeutics
CGTX
$79.6M
$4.56M 8.63%
6,000,000
– –
RNTX
4
Rein Therapeutics
RNTX
$63.1M
$2.58M 4.87%
1,982,375
+291,624
+17% +$362K
LTRN icon
5
Lantern Pharma
LTRN
$33.6M
$1.18M 2.24%
864,435
-145,072
-14% -$406K
INAB icon
6
IN8bio
INAB
$9.88M
$248K 0.47%
167,805
-85,612
-34% -$166K

Similar funds

FRGX
First Reserve GP XIII Stamford, Connecticut $52.9M AUM 17.37% 1-Year Est. Return
ICM
Irth Capital Management New York $52.8M AUM 21.11% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
GMEI
Global Media & Entertainment Investments Nassau, Bahamas $53M AUM 0% 1-Year Est. Return
TP
Toronado Partners San Francisco, California $53M AUM 13.38% 1-Year Est. Return
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53.2M AUM 13.56% 1-Year Est. Return
WEO
William E. Oberndorf $53.3M AUM 10.89% 1-Year Est. Return
NCM
Notable Capital Management Menlo Park, California $53.4M AUM 10.98% 1-Year Est. Return

BIOS Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, BIOS Capital Management held 6 positions worth $52.9M, down 36% from $82.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2026: portfolio turnover was 0%. BIOS Capital Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BIOS Capital Management added most to Rein Therapeutics in Q1 2026, an estimated $362K increase.
  • BIOS Capital Management's biggest Q1 2026 reduction was Lantern Pharma, cutting an estimated $406K.
  • BIOS Capital Management's ten largest holdings make up 100% of its $52.9M portfolio in Q1 2026.
  • BIOS Capital Management opened 0 new positions and closed 0 in Q1 2026.
  • BIOS Capital Management's portfolio value fell 36% quarter-over-quarter to $52.9M.

Based on BIOS Capital Management's 13F filing for Q1 2026, filed 13 May 2026.